Hepatitis C is a current pandemic liver disease caused by the hepatitis C virus (HCV) with high morbidity
and mortality. Recently, the direct-acting antiviral agents (DAAs) targeting HCV NS3/4A, NS5A and
NS5B have become the most effective therapies against HCV infection in the clinical treatment. Among them,
the second-generation of NS3/4A inhibitors have emerged as the mainstay of the DAA therapies, which are derived
from the peptide substrate of NS3/4A protease and modified with various tailor-made amino acids in order
to achieve high sustained virologic response (SVR) against HCV. This review summarizes sixteen examples of
the second-generation of HCV NS3/4A inhibitors, mainly focusing on the clinical application, structure development,
structure-activity relationship (SAR) and their synthesis.
Keywords: Hepatitis C virus (HCV), pandemic, direct-acting antiviral agents (DAAs), NS3/4A protease inhibitor, tailor-made amino acids,
structure-activity relationship (SAR), asymmetric synthesis, ring-closing metathesis (RCM).
Rights & PermissionsPrintExport